• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles named to Fortune magazine's 2015 list of World’s Most Admired Companies

Quintiles named to Fortune magazine's 2015 list of World’s Most Admired Companies

February 26, 2015
CenterWatch Staff

Quintiles, a biopharmaceutical services company, has been named to Fortune magazine’s World’s Most Admired Companies list for 2015.

Quintiles is ranked third overall in Fortune’s Healthcare: Pharmacy and Other Services category with the top ranking for the reputation attribute of global competitiveness and second within the segment for its people management.

Fortune's World's Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, Fortune has identified, selected and ranked the World’s Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers. 

“I would like to congratulate Quintiles’ employees around the world for making this possible,” said Tom Pike, Quintiles CEO. “Being named one of the World’s Most Admired Companies is a significant milestone in the history of our company.  It is recognition that Quintiles is headed in the right direction to deliver value for customers as we improve their probability of success. It now is up to all of us in the organization to live up to these expectations.”

Quintiles recently entered its 33rd year of operation, having been established at the University of North Carolina at Chapel Hill in 1982 by biostatistics professors Dr. Dennis Gillings, CBE and Gary Koch, Ph.D.  The company, which once operated out of a trailer on the UNC campus, now conducts business in approximately 100 countries. 

More than three decades later, Quintiles is the world’s largest provider of biopharmaceutical development and commercial outsourcing services as the company helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market (2014 statistics pending).  

During 2014, Quintiles was recognized as the Best CRO in the U.K. SCRIP awards, named Asia CRO of the Year by Frost and Sullivan, voted Best CRO in Asia in the BioPharma Asia Industry Awards and was named Best Contract Sales Organization in the PharmaField awards, as well as being named to the Fortune 500 for the first time.

The survey employed by Fortune to designate its World’s Most Admired Companies list assesses nine reputation drivers considered to be crucial to a company’s global success including financial soundness, long-term investment value, people management, social responsibility, use of assets, quality of management, quality of products/services, innovation and global competitiveness.

These attributes were developed prior to the inception of the Most Admired Companies rankings in the mid-1980s through a series of interviews with executives and industry analysts to determine the qualities that make a company worthy of admiration.

Raters are asked to evaluate each eligible company on attributes by assigning a score from zero (Poor) to 10 (Excellent). For the purposes of the industry rankings, a company’s overall score is determined through a simple average of the individual attribute scores. Companies who rank in the top half of their industry are defined as most admired within their industry.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing